



Published in final edited form as:

Structure. 2022 September 01; 30(9): 1224–1232.e5. doi:10.1016/j.str.2022.05.020.

Binding of the SARS-CoV-2 envelope E protein to human BRD4 is essential for infection

Kendra R. Vann^{1,6}, Arpan Acharya^{2,6}, Suk Min Jang^{3,6}, Catherine Lachance³, Mohamad Zandian¹, Tina A. Holt¹, Audrey L. Smith⁴, Kabita Pandey², Donald L. Durden⁵, Dalia El-Gamal⁴, Jacques Côté^{3,*}, Siddappa N. Byrareddy^{2,*}, Tatiana G. Kutateladze^{1,7,*}

¹Department of Pharmacology, University of Colorado School of Medicine, Aurora, CO 80045, USA

²Department of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, Omaha, NE 68131, USA

³Laval University Cancer Research Center, CHU de Québec-UL Research Center-Oncology Division, Quebec City, Québec G1R 3S3, Canada

⁴Eppley Institute for Research in Cancer and Allied Diseases, Fred & Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, NE 68131, USA

⁵Division of Hematology and Oncology, Department of Pediatrics, Moores Cancer Center, University of California San Diego, La Jolla, CA 92130, USA

Summary

Emerging new variants of SARS-CoV-2 and inevitable acquired drug resistance call for the continued search of new pharmacological targets to fight the potentially fatal infection. Here, we describe the mechanisms by which the E protein of SARS-CoV-2 hijacks the human transcriptional regulator BRD4. We found that SARS-CoV-2 E is acetylated *in vivo* and co-immunoprecipitates with BRD4 in human cells. Bromodomains (BDs) of BRD4 bind to the C-terminus of the E protein, acetylated by human acetyltransferase p300, whereas the ET domain of BRD4 recognizes the unmodified motif of the E protein. Inhibitors of BRD4 BDs, JQ1 or OTX015, decrease SARS-CoV-2 infectivity in lung bronchial epithelial cells, indicating that the acetyllysine binding function of BDs is necessary for the virus fitness and that BRD4 represents a potential anti-COVID-19 target. Our findings provide insight into molecular mechanisms that

*Correspondence: tatiana.kutateladze@cuanschutz.edu, sid.byrareddy@unmc.edu, jacques.cote@crchudequebec.ulaval.ca.

⁶Equal contribution

⁷Lead Contact

Authors contributions

K.R.V., A.A., S.M.J., C. L., M.Z., T.A.H., A.L.S., and K.P. performed experiments and together with D.L.D., D.E.G., J.C., S.N.B. and T.G.K. discussed and analyzed the data. K.R.V. and T.G.K. wrote the manuscript with input from all authors.


Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Declaration of interest

The authors declare no competing interests.

contribute to SARS-CoV-2 pathogenesis and shed light on a new strategy to block SARS-CoV-2 infection.

Graphical Abstract



eTOC Blurp

SARS-CoV-2 virus uses host molecular programs for viral replication and survival in infected cells. Vann et al. identified mechanisms by which the E protein of SARS-CoV-2 interacts with the human transcriptional regulator BRD4.

Keywords

SARS-CoV-2; envelope E protein; BRD4; bromodomain; ET domain

Introduction

The novel coronavirus SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) continues posing an immense threat to public health. This pathogen causes severe respiratory distress and pneumonia and has led to the disastrous viral infection pandemic with morbidity reaching 305 million as of January 2022. SARS-CoV-2 relates to other beta-coronaviruses SARS-CoV and MERS-CoV, which triggered outbreaks in 2002 and 2012 and have similar genomes and host cell entry mechanisms. The ~30kb single-stranded RNA genome of SARS-CoV-2 encodes four structural proteins, spike (S), envelope (E), nucleocapsid (N), and membrane (M), all of which are involved in multiple aspects of the SARS-CoV-2 life cycle, including the virion particle assembly, viral entry, fusion of viral and host cell membranes and the virus replication (Li et al., 2021). The E protein of SARS-CoV-2 is the smallest structural protein, containing only 75 amino acids. Although it remains poorly characterized, homologous SARS-CoV E has been shown to play a vital role in virus production, maturation and budding (DeDiego et al., 2007; Schoeman and Fielding, 2019).

The amino-terminal transmembrane domain of SARS-CoV E can oligomerize, forming the ion-conductive pores in membranes (Nieto-Torres et al., 2014; Schoeman and Fielding, 2019; Verdia-Baguena et al., 2012). Deletion of SARS-CoV E diminishes virus virulence, and immunization of mice with recombinant SARS-CoV lacking the E protein was found to protect the mice against lethal disease, demonstrating that the E protein is an essential virulence factor (Netland et al., 2010).

Affinity-purification mass spectrometry analysis has identified over 300 high-confidence interactions between human proteins and the SARS-CoV-2 proteins (Gordon et al., 2020). Among them are the SARS-CoV-2 E protein and human bromodomain and extra-terminal domain (BET) proteins BRD2 and BRD4. Of the four members of the BET family proteins, BRD4 has received considerable attention as a pharmacological target for the treatment of a wide array of human diseases (Filippakopoulos and Knapp, 2014; Lambert et al., 2019). BRD4 contains two tandem bromodomains (BDs), bromodomain 1 (BD1) and bromodomain (BD2), which bind to acetylated lysine residues, and the extra-terminal (ET) domain, which recognizes the KhKh (h; hydrophobic residue) motif found in LANA, CHD4 and NSDs (Zhang et al., 2016) (Figure 1a). BRD4 BD1 is primarily known to interact with acetylated histones, such as poly-acetylated histone H4, whereas BRD4 BD2 also associates with acetylated non-histone proteins (Shi et al., 2014). Both interactions help recruit BRD4-containing transcription complexes to promoters of target genes and are linked to active gene transcription (Filippakopoulos et al., 2012). The basis of the potential link between BRD4 and the E protein of SARS-CoV-2 remains undetermined.

Here, we identified two mechanisms by which the E protein of SARS-CoV-2 hijacks the human transcriptional regulator BRD4. BD1 and BD2 of BRD4 associate with acetylated K53 and K63 of the E protein (SARS-CoV-2 E^{K53ac} and E^{K63ac}, respectively), preferring the diacetylated sequence (SARSCoV-2 E^{K53ac/K63ac}), whereas the ET domain of BRD4 binds to the SFYVYSRVKLN motif of the E protein (SARS-CoV-2 E⁵⁵⁻⁶⁶). We show that the E protein can be acetylated by human acetyltransferase p300, and that the SARS-CoV-2 infection is reduced by blocking BDs with the BET inhibitors JQ1 or OTX015. Our findings point to a new strategy to combat SARS-CoV-2 infection.

Results and discussion

The E protein of SARS-CoV-2 contains only two lysine residues, K53 and K63, located at the C-terminus of the protein amino acid sequence (Figure 1a). We used a combination of structural, biochemical, and enzymatic approaches to explore the idea that these lysine residues could be acetylated in the cell by human enzymes and subsequently recognized by bromodomains of human BRD4. The FLAG tagged SARS-CoV-2 E protein was expressed in 293T cells and its acetylation on lysine residues *in vivo* was confirmed by immunoprecipitation with anti-acetyl-lysine antibodies from whole cell extracts (Figures 1b and S1). Immunoprecipitation with anti-FLAG beads on the same extracts followed by western blot with BRD4 antibodies also confirmed the interaction of the FLAG tagged SARS-CoV-2 E protein with BRD4 (Figure 1c).

To test whether the SARS-CoV-2 E protein can be acetylated by human acetyltransferases, we performed *in vitro* acetyltransferase assays using a set of acetyltransferases known to acetylate histone and non-histone proteins. As shown in Figure 1d, recombinant p300 efficiently acetylated the SARS-CoV-2 E^{48–72} peptide (aa 48–72 of SARS-CoV-2 E), though the level of E peptide acetylation was lower than the level of acetylation of histone H3, a known substrate of p300 (Figure 1e). While acetylation of the SARS-CoV-2 E^{48–72} peptide by the human HAT complexes SAGA and NuA4/TIP60 was undetectable, the native human MYST-family HAT complexes purified via MEAF6 (MYST) or BRPF2 (HBO1) subunits were also able to some extent acetylate the SARS-CoV-2 E^{48–72} peptide.

The binding of BRD4 BDs to diacetylated SARS-CoV-2 E^{K53ac/K63ac} (aa 53–64 of SARS-CoV-2 E) peptide was evident in NMR experiments. Titration of SARS-CoV-2 E^{K53ac/K63ac} into the ¹⁵N-labeled BRD4 BD1 NMR sample led to large chemical shift perturbations (CSPs), and saturation was reached with a two-fold excess of the SARS-CoV-2 E^{K53ac/K63ac} peptide (Figure 1f). Binding affinity of BD1 for SARS-CoV-2 E^{K53ac/K63ac}, measured via chemical shift perturbations analysis, was found to be 36 μ M (Figure S2). Similarly, BD2 of BRD4 formed a complex with SARS-CoV-2 E^{K53ac/K63ac} based on CSPs in the intermediate exchange regime ($K_d = 30 \mu$ M) (Figures 1g and S2). While BRD4 BD2 was capable of binding to both monoacetylated SARS-CoV-2 E^{K63ac} (aa 60–68 of SARS-CoV-2 E) and SARS-CoV-2 E^{K53ac} (aa 50–55 of SARS-CoV-2 E) peptides (K_d s = 200 μ M and 710 μ M, respectively), BD1 selected for acetylated K63 ($K_d = 660 \mu$ M) over acetylated K53 ($K_d > 1$ mM) (Figures 1f, g and S2).

To gain insight into the mechanistic basis of the BRD4-E interaction, we co-crystallized BRD4 BD1 with the diacetylated SARS-CoV-2 E^{K53ac/K63ac} peptide and determined the crystal structure of the complex to 2.6 \AA resolution (Figures 2a, b and S3 and Table 1). The structure shows that two molecules of BD1 are engaged with one SARS-CoV-2 E^{K53ac/K63ac} peptide. BRD4 BD1 adopts a four-helix bundle fold with K53ac of the SARS-CoV-2 E^{K53ac/K63ac} peptide bound by one BD1 molecule, whereas K63ac of the peptide was bound by another BD1 molecule (Figure 2a). The side chains of both K53ac and K63ac, being in an extended conformation, insert deep into the hydrophobic pockets at the top of the α -helical bundles (Figure 2b). The characteristic hydrogen bonds with the side chain amide nitrogen of N140 of both BD1 molecules restrain the carbonyl oxygen of the acetyl groups of K53ac and K63ac of the peptide. The complex is further stabilized through the formation of hydrogen bonds between the hydroxyl group of Y59 of SARS-CoV-2 E^{K53ac/K63ac} and the backbone carbonyl group of W81 and the side chain amide of Q85 of one BD1 molecule. The backbone carbonyl group of L92 from another BD1 molecule is hydrogen bonded to the hydroxyl group of S55 of SARS-CoV-2 E^{K53ac/K63ac}. The residues F56-R61 of SARS-CoV-2 E^{K53ac/K63ac} form an α -helix which positions K53ac and K63ac for the simultaneous interaction with two BDs, and interestingly, this region adopts an α -helical conformation in the structure of the homologous SARS-CoV E protein (Figure 2c) (Surya et al., 2018). The crystal structure of BRD4 BD1 in complex with monoacetylated SARS-CoV-2 E^{K63ac} (aa 60–68 of SARS-CoV-2 E) peptide superimposes with the structure of the BD1-SARS-CoV-2 E^{K53ac/K63ac} complex with a rmsd of 0.4 \AA , revealing a conserved mode of acetyllysine recognition (Figure 2d).

Notably, the SARS-CoV-2 E protein contains the sequence RVK⁶³N which resembles the KhKh motif that is recognized by the ET domain of BRD4 (Figures 1a and 3a). To test the idea that the BRD4 ET domain binds to the unmodified E protein, we titrated SARS-CoV-2 E^{55–66} (aa 55–66 of SARS-CoV-2 E) into the BRD4 ET NMR sample (Figure 3b). CSPs and disappearance of the ET resonances pointed to an interaction, which was confirmed by measuring K_d for the BRD4 ET-E^{55–66} complex by microscale thermophoresis (MST) ($K_d=50 \mu\text{M}$) (Figure 3c). The longer peptide SARS-CoV-2 E^{53–72} (aa 53–72 of SARS-CoV-2 E) did not alter the pattern of CSPs in BRD4 ET, indicating that the SARS-CoV-2 E^{55–66} sequence is sufficient for the interaction, however removing S55 and F56 in the SARS-CoV-2 E^{57–69} (aa 57–69 of SARS-CoV-2 E) peptide led to small CSPs, suggesting that SF⁵⁶ is necessary for binding of BRD4 ET. Mapping CSPs caused by SARS-CoV-2 E^{55–66} onto the structure of BRD4 ET delineated the binding interface, which encompasses the groove formed by $\alpha 1$ and $\alpha 2$ helices and the loop between $\alpha 2$ and $\alpha 3$ of the ET domain (Figure 3d, e).

BRD4 is known to mediate immune and inflammatory responses to viral infection and was recently reported to regulate COVID-19 mediated cytokine storm and cardiac damage (Mills et al., 2021). Furthermore, BET inhibitors were shown to downregulate the expression of viral host entry factors, such as angiotensin-converting enzyme 2 (ACE2), thereby limiting SARS-CoV-2 replication *in vitro* (Gilham et al., 2021; Qiao et al., 2020), and have potent anti-viral activity (Acharya et al., 2022; Qiao et al., 2020; Samelson et al., 2022). To examine the importance of the BRD4-E interaction for the SARSCoV-2 lifecycle, we infected the human lung bronchial epithelial cell line Calu-3 with a Delta variant of SARS-CoV-2 (pangolin lineage B.1.617.2) and monitored infection by immunofluorescence (Figure 4a, b). As shown in Figure 4b, the addition of inhibitors of BRD4, JQ1 or OTX015, led to a decrease in Spike SARS-CoV-2 protein staining (green), indicating that the acetyllysine binding activity of BDs is necessary for the virus fitness. At the concentration of 0.01 μM , JQ1 and OTX015 inhibited SARS-CoV2 infection in Calu-3 cells by 72% and 69%, respectively, and showed low cytotoxicity with Calu-3 cell viability being 100% for JQ1-treated cells and 98% for OTX015-treated cells (Figure 4c, d). Based on viral loads in the culture supernatant of Calu-3 cells, JQ1 showed anti-viral activity with an IC_{50} of 0.12 μM and OTX015 showed anti-viral activity with an IC_{50} of 0.11 μM against the Delta variant of SARSCoV-2 (Figure 4e, f). These data suggest that the disruption of acetyllysine binding activity of BRD4 might represent a novel approach to combat the infection.

Collectively, in this study we identified the molecular basis underlying SARS-CoV-2 association with the transcriptional activator BRD4 and show that the interaction between BRD4 and the E protein is essential for SARS-CoV-2 pathogenesis in human cells. We found that the full-length SARS-CoV-2 E protein is acetylated *in vivo* and co-immunoprecipitates with BRD4 in 293T cells and that the C-terminus of SARS-CoV-2 E can be acetylated *in vitro* by human acetyltransferases, such as p300. The interaction between BRD4 BDs and acetylated SARS-CoV-2 E represents yet another example that highlights how vital host cell signaling programs can be hijacked by posttranslationally modified viral proteins. Posttranslational modifications (PTMs) of viral proteins, such as phosphorylation, ubiquitination, methylation and acetylation, installed by host enzymes during infection have been shown to play essential roles in the virus replication, fusion with the host membrane

and localization in the host cell, as well as in host defense (reviewed in (Kumar et al., 2020; Murray et al., 2019)). Acetylation of Tat, a human immunodeficiency virus HIV-1 protein, the influenza A protein NP, and the pUL26 protein of the human cytomegalovirus affects virulence properties, production of viral proteins, and virus replication and assembly (Kumar et al., 2020; Murray et al., 2019). Interestingly, it has been demonstrated that the E2 protein of papillomaviruses is acetylated by p300 (Jose et al., 2021) and that methylated non-structural protein 1 (NS1) from H3N2-subtype influenza A binds to histone readers (Marazzi et al., 2012; Qin et al., 2014; Zhang et al., 2019).

Our findings point to a new strategy to block SARS-CoV-2 infection and aid in our understanding of how SARS-CoV-2 targets host cell signaling pathways and alters immune responses. Future studies are needed to address important questions, including whether BDs and the ET domain of BRD4 can be engaged with the E protein simultaneously. It will also be essential to establish which domain in BRD4 is the preferred target and whether the BRD4-SARS-CoV-2 E interactions are conserved in other BET family proteins and what biological roles they may play.

Star Methods

Resource availability

Lead contact—Further information and requests for resources and reagents should be directed to and will be fulfilled by the lead contact, Tatiana G. Kutateladze (tatiana.kutateladze@cuanschutz.edu).

Materials availability

All expression plasmids used in this study will be made available on request. This study did not generate new unique reagents.

Data and code availability

Coordinates and structure factors have been deposited in the Protein Data Bank under the accession codes 7TV0 and 7TUQ. Other data reported in this paper will be shared by the lead contact upon request. This paper does not report original code. Any additional information required to reanalyze the data reported in this paper is available from the lead contact upon request.

Experimental model and subject details

The BD1 and BD2 domains of BRD4 were expressed in BL21 (DE3) RIL in LB or minimal media supplemented with $^{15}\text{NH}_4\text{Cl}$. Protein expression was induced with 1 mM IPTG for 16 h at 18°C. The ET domain of BRD4 was expressed in Tuner (DE3) cells in minimal media supplemented with $^{15}\text{NH}_4\text{Cl}$. Protein expression was induced with 0.5 mM IPTG for 16 h at 18°C. The native MYST-family HAT complexes MEAF6 (MYST) and BRPF2 (HBO1) were purified by tandem affinity steps (3xFlag-2xStrep) from human K562 cells expressing endogenously tagged MEAF6 or BRPF2 from the AAVS1 safe harbour. Human bronchial epithelial Calu-3 cells (ATCC, Manassas, VA, USA) were maintained in complete medium [Eagle's Minimum Essential Medium (EMEM) ATCC] supplemented with 10% fetal bovine

serum (FBS), 100 U/mL penicillin, and 100 µg/mL streptomycin (P/S). Human Kidney 293T (ATCC, CRL-3216) were maintained in complete medium DMEM supplemented with 10% fetal bovine serum (FBS) and Human bone marrow K652 (ATCC, CCL-243) were maintained in complete medium RPMI with 10% New Born Calf Serum (NBCS).

Method details

Cloning and protein expression and purification—pGEX6P-1 BRD4 bromodomain 1 (residues 43–180) and pGEX4T-1 BRD4 bromodomain 2 (residues 342–460) constructs were expressed in *Escherichia coli* BL21 (DE3) RIL cells in Luria Broth or minimal media supplemented with $^{15}\text{NH}_4\text{Cl}$. The cells were cultured at 37 °C, induced with a final concentration of 1 mM IPTG and cultured for 16 h post-induction at 18 °C. Cells were harvested by centrifugation at 5000 rpm. The cells were resuspended in 50 mM HEPES pH 7.5, 150 mM NaCl and 1 mM TCEP, lysed by sonication, and the lysate was cleared by centrifugation at 15000 rpm. Unlabeled and ^{15}N -labeled BRD4 BD1 or BD2 domains were purified on glutathione Sepharose 4B beads, and the GST tag was cleaved with PreScission (BD1) or thrombin (BD2) protease. The cleaved protein was concentrated using a 3 kDa CO concentrator and further purified by FPLC using a HiPrep Sephacryl S-100 HR column (GE) in 10 mM HEPES pH 7.5, 100 mM NaCl, 1 mM TCEP. Protein fractions were checked for purity by SDS-PAGE and concentrated to ~9–20 mg/ml.

The pET32a BRD4 ET domain (600–700) vector was a gift from Tim McKinsey. The TRX-6His-Stagged ET domain was expressed in *Escherichia coli* Tuner (DE3) cells in minimal media supplemented with $^{15}\text{NH}_4\text{Cl}$. Cells were cultured at 37 °C, induced with a final concentration of 0.5 mM IPTG, cultured for 16 h post-induction at 18 °C and harvested by centrifugation at 5000 rpm. Cells were resuspended in 20 mM sodium phosphate (pH 7.0) buffer, supplemented with 500 mM NaCl, 10 mM imidazole and 2 mM BME, lysed by sonication, and the lysate was cleared by centrifugation at 15000 rpm. Unlabeled and ^{15}N -labeled His-tagged ET domain was purified on Nickel-NTA resin (ThermoScientific). The tagged protein was eluted using a 30–300 mM imidazole gradient elution. The eluted protein was first buffer exchanged into cleavage buffer containing 20 mM Tris pH 8.0, 50 mM NaCl, 2 mM CaCl_2 and then cleaved overnight at RT with enterokinase protease (NEB). The ET domain was further purified using Nickel-NTA resin (Thermo Scientific) and ion exchange using a HiTrap SP column (Cytiva) to remove the cleaved tag. Size-exclusion chromatography was performed using a Superdex S75 column (Cytiva). The purified protein was buffer exchanged into 20 mM Tris pH 7.0, 100 mM NaCl, 5 mM DTT, concentrated to ~10 mg/mL using 3 kDa Millipore concentrator.

The full-length SARS-CoV-2 E sequence was synthesized by gBlock (IDT) and amplified by PCR with BamHI and XhoI restriction sites for ligation in the BamHI and XhoI digested pcDNA3 3xFlag plasmid.

NMR spectroscopy—NMR experiments were carried out on a Varian INOVA 600 MHz spectrometer equipped with a cryogenic probe at 298 K. The ^1H , ^{15}N heteronuclear single quantum coherence (HSQC) spectra of 0.2 mM uniformly ^{15}N -labeled BRD4 BD1 and BRD4 BD2 were collected in the presence of increasing concentrations of indicated SARS-

CoV-2 peptides in PBS buffer, pH 6.8, 10% D₂O. ¹H, ¹⁵N HSQC spectra of 0.15 mM uniformly ¹⁵N-labeled BRD4 ET were collected in the presence of increasing concentrations of indicated SARS-CoV-2 peptides (diluted to a stock of 50 mM in 50%–100% DMSO) in 20 mM Tris pH 7.0, 100 mM NaCl, 3 mM DTT and 10% D₂O. NMR data were processed with NMRPipe. NMR assignments for BRD4 ET were taken from (Zhang et al., 2016). Control experiments, demonstrating that the BRD4 ET domain is not perturbed by DMSO and BRD4 BD1 does not bind to non-acetylated SARS-CoV-2 peptide (aa 53–72) are shown in Figure S4.

The dissociation constants (K_{dS}) were determined by a nonlinear least-squares analysis in GraphPad Prism using the equation:

$$\Delta\delta = \Delta\delta_{\max} \left(([L] + [P] + K_d) - \sqrt{([L] + [P] + K_d)^2 - 4[P][L]} \right) / 2[P]$$

where [L] is concentration of the peptide, [P] is concentration of the protein, $\Delta\delta$ is the observed chemical shift change, and δ_{\max} is the normalized chemical shift change at saturation. Normalized chemical shift changes were calculated using the equation $\Delta\delta = \sqrt{(\Delta\delta_H)^2 + (\Delta\delta_N/5)^2}$, where δ is the change in chemical shift in parts per million (ppm).

X-ray crystallography—BRD4 BD1 (residues 43–180) was incubated with 2 molar equivalence of peptide at 4 °C overnight and then dialyzed against 10 mM HEPES pH 7.5, 100 mM NaCl, 1 mM TCEP. The dialyzed protein-peptide mixtures were concentrated to 7–15 mg/ml. Crystals of BRD4 BD1 in complex with SARS-CoV-2 E peptides were grown by the sitting-drop or hanging-drop vapor diffusion method in a 0.6–3 μ l drop using 1:1 or 1:2 ratio of protein/peptide: reservoir solution at 18 °C. Crystals of BRD4 BD1 in complex with Ac-SRVK(ac)NLNSS-NH₂ SARS-CoV-2 E^{K63ac} peptide (aa 60–68) were formed in a sitting-drop and BRD4 BD1 in complex with dual acetylated SARS-CoV-2 E^{K53ac/63ac} peptide (aa 53–64) were formed in a hanging-drop against the reservoir solution (1.5 M ammonium sulfate, 100 mM Tris pH 8.5 and 12% glycerol). X-ray diffraction datasets for the complexes were collected at 100 K on a Rigaku Micromax 007 high-frequency microfocus X-ray generator with a Pilatus 200K 2D area detector (University of Colorado Anschutz X-ray core facility). The data were indexed and scaled using XDS (Kabsch, 2010). Phase solutions were determined by molecular replacement in Phaser (McCoy et al., 2007) using an edited version of BRD4 BD1 (PDB IDs: 3JVK and 3UVW) as search models. Refinement was performed in PHENIX Refine (Adams et al., 2002) and manually by Coot (Emsley and Cowtan, 2004).

Affinity purifications of native histone acetyltransferase complexes—Native HBO1 (BRPF2) and MYST (MEAF6) acetyltransferase complexes were purified by Tandem Affinity Purification (TAP, 3Flag-2Strep) as described (Dalvai et al., 2015).

Acetyltransferase assays—Acetyltransferase assays with recombinant p300 (catalytic domain, ActiveMotif, Cat # 81093) or purified native human histone acetyltransferase complexes were performed in a volume of 15 μ l. The native MYST-family HAT

complexes MEAF6 (MYST) and BRPF2 (HBO1) were purified by tandem affinity steps (3xFlag-2xStrep) from human K562 cells expressing endogenously tagged MEAF6 or BRPF2 from the AAVS1 safe harbour (Dalvai et al., 2015; Klein et al., 2019). Mock purification from K562 cells expressing an empty tag was used as control. 0.1 µg of p300 was used in the reactions with the E peptide and 0.2 µg of p300 was used in the reactions with the histone peptides. The reaction mixtures containing 0.5 µg of the E peptide (aa 48–72 of E) or recombinant H3 peptide (aa 1–29 of H3) as substrates and 0.125 µCi of ³H labeled Ac-CoA (2.1 Ci/mmol; PerkinElmer Life Sciences) in buffer 50 mM Tris-HCl pH 8, 50 mM KCl, 10 mM sodium butyrate, 5% glycerol, 0.1 mM EDTA, 1 mM dithiothreitol were incubated for 30 minutes at 30 °C. The reactions were then spotted on P81 filter paper, and the free ³H-labeled Ac-CoA was washed away with 50 mM NaHCO₃-Na₂CO₃ pH 9.2. The filter was rinsed with acetone, dried, and then analyzed using Liquid Scintillation.

Microscale Thermophoresis (MST)—FAM-labeled SARS-CoV-2 E peptide (Synpeptide) was diluted to a stock of 50 mM in 100% DMSO. Working concentrations were diluted in 20 mM Tris pH 7.0, 100 mM NaCl, 3 mM DTT, 0.05% Tween 20 with a final concentration of 5% DMSO, which was also used as assay buffer for MST experiments. FAM-labeled peptide was used as the target at a concentration of 500 nM, while non-labeled ET protein was titrated in a 1:1 dilution series (1–200 µM). Samples were mixed, centrifuged and loaded into premium-treated capillaries (NanoTemper Technologies) and measured using a Monolith NT.115 pico and MO.Control software (excitation power setting 100%, NanoBlue, MST power 40%). Data were analyzed using MO.Affinity Analysis software (NanoTemper Technologies) at the standard MST-on time of 5 s.

Cell culture—Human bronchial epithelial Calu-3 cells (ATCC, Manassas, VA, USA) were maintained in complete medium [Eagle's Minimum Essential Medium (EMEM) ATCC] supplemented with 10% fetal bovine serum (FBS), 100 U/mL penicillin, and 100 µg/mL streptomycin (P/S). Human Kidney 293T (ATCC, CRL-3216) were maintained in complete medium DMEM supplemented with 10% fetal bovine serum (FBS) and Human bone marrow K652 (ATCC, CCL-243) were maintained in complete medium RPMI with 10% New Born Calf Serum (NBCS).

Co-Immunoprecipitation—Human kidney 293T cells at 80%–90% confluency in D150 mm plate (~1.6×10⁷ cells) were transfected with 20 µg of pcDNA3 (empty FLAG, Invitrogen, Cat # V79020) or pcDNA3 SARS-CoV-2 E 3xFLAG with lipofectamine 3000 (Invitrogen, Cat # L3000001) according to manufacturer's instructions. Cells were harvested 76 h post-co-transfection and lysed in 500 µl of WCE buffer (450 mM NaCl, 50 mM Tris-HCl (pH 8.0), 1% TX-100, 2 mM MgCl₂, 0.1 mM ZnCl₂, 2 mM EDTA, 10% glycerol) supplemented with protease inhibitor mixture. The NaCl concentration was reduced to 225 mM, and the whole cell extract was centrifuged at 14,000 rpm for 30 min. The FLAG SARS-CoV-2 E was immunoprecipitated from the soluble fraction using 50 µl anti-FLAG M2 affinity beads (Sigma-Aldrich, Cat # A2220) for 2 h at 4°C on a rotating wheel or with 6 µg of anti-acetyl-lysine antibody (ImmuneChem, Cat # ICP0380) for 3 h at 4°C on a rotating wheel and followed by incubation with 50 µl protein G-Sepharose beads (Dynabeads Invitrogen, 10002D). The immunoprecipitation was eluted in 45 µl of 1xLaemmli Buffer

at 95°C for 10 minutes. 1% Input and 15 µl of immunoprecipitations were used for western blotting. Anti-FLAG M2 conjugated to horseradish peroxidase (Sigma-Aldrich, Cat # A8592) was used at a 1:10,000 dilution, and the immunoblots were visualized using a Western Lightning plus-ECL reagent (PerkinElmer). Anti-BRD4 (Abcam, Cat # ab46199) was used at a 1:1,000 dilution. Uncropped western blots are shown in Figure S5.

SARS-CoV-2 (Delta variant) infection of Calu-3 cells and BRD4 inhibitor studies

—All live virus experiments were performed in the BSL3 laboratory at the University of Nebraska Medical Center (Omaha, NE, USA). Calu-3 cells were plated in a 96 well transparent bottom black color plate (15000 cells/well) and cultured for 48 hours before infection. On the day of infection, the cells were treated with different concentrations of JQ1 (Cayman Chemical, Cat # 11187) or OTX015 (Cayman Chemical, Cat # 15947) (0.1 µM to 0.001 µM) two hours before infection. The cells were infected with SARS-CoV-2 (Delta variant of concern (VOC); pangolin lineage: B.1.617.2, obtained from BEI Resources, NIAID, NIH; cat # 55672) with 0.5 MOI of viral titer or left uninfected (negative control). One hour post-infection, virus inoculum was removed from the cells, washed 3 times with 1X PBS, replenished with fresh media and treated with respective compounds. The reaction was terminated 24 hours post-infection. The culture supernatant was collected for measuring the viral replication kinetics, and the cells were washed and fixed with 4% PFA for immunofluorescence analysis.

Viral replication kinetics using RT-qPCR—The SARS-CoV-2 viral load in the cells was determined as described (Acharya et al., 2021). Briefly, RT-qPCR was performed on a set of primers targeting the E gene of SARS-CoV-2 using PrimeDirect Probe RT-qPCR Mix (TaKaRa Bio USA, Inc) and Applied Biosystems QuantStudio3 real-time PCR system (Applied Biosystems, Waltham, MA, USA). The SARS-CoV-2 genome equivalent copies were calculated by quantitative PCR control RNA from heat-inactivated SARS-CoV-2, isolate USA-WA1/2020 (BEI, Catalog# NR-52347). The percent inhibition of SARS-CoV-2 replication by JQ1 and OTX015 treatment was measured based on viral concentration in positive control wells (considered 0% inhibition) and negative control wells (uninfected cells). IC₅₀ values were calculated using four-parameter variable slope sigmoidal dose-response models using Graph Pad Prism 9.0 software.

Immunofluorescence—The 4% PFA fixed Calu-3 cells were washed three times with 1X PBS and permeabilized by adding 50 µl of 0.1% Triton X-100. Blocking was performed in 3% bovine serum albumin-phosphate buffered saline for 2 hours. Then, 50 µl of the primary antibody against the Spike glycoprotein of SARS-CoV-2 (Sino biological, Cat # MA14AP0204) was added at a 1:1,000 dilution, and cells were incubated overnight at 4°C on a shaker. The cells were washed three times with 1X PBS, and 50 µl of secondary antibody AlexaFluor 488 Goat anti-rabbit (Thermo Fisher, Cat # A-11034) was added per well at a 1:2,000 dilution. The reactions were incubated for 1 hour in the dark at room temperature on a shaker. The reactions were incubated at room temperature on a shaker for 1 hour in the dark. The cells were then washed once with 1X PBS, stained with Hoechst 33258 (Invitrogen, Cat # H3570) and Cell Mask (Invitrogen, Cat # C10046) to visualize the

nucleus and cytoplasm. Images were captured using a high content analysis system at 20X air on an Operetta CLS. Data were analyzed with the Harmony analysis software.

Quantification and statistical analysis—The crystal structure of the BRD4 BD1 domain in complex with mono- and diacetylated E peptides were determined using materials and softwares listed in the Key Resources Table. Statistics generated from X-ray crystallography data processing, refinement, and structure validation are displayed in Table 1. Data shown in Figure 1d, e represent mean of three independent measurements, and error represents SD. $n = 3$ Data shown in Figure 4c–f represent mean of three replicates, and error bars represent SEM. $n = 3$ IC₅₀ values shown in Figure 4e, f were calculated using four-parameter variable slope sigmoidal dose-response models using Graph Pad Prism 9.0 software.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

This work was supported in part by grants from the NIH: HL151334, CA252707, GM125195, GM135671 and AG067664 to T.G.K. and AI129745 and DA052845 to S.N.B., and a foundation grant from the CIHR to J.C (FDN-143314). S.N.B. acknowledges independent research and development (IRAD) funding from the National Strategic Research Institute (NSRI) at the University of Nebraska. J.C. holds the Canada Research Chair on Chromatin Biology and Molecular Epigenetics. We acknowledge the UNMC BSL-3 core facility at DRC-1 where experiments involving live SARS-CoV-2 were performed and St Patrick Reid laboratory for the use of Operetta CLS. UNMC BSL-3 core facility is administered by the office of the Vice-Chancellor for research and supported by the Nebraska Research Initiative (NRI).

References

- Acharya A, Pandey K, Thurman M, Klug E, Trivedi J, Sharma K, Lorson CL, Singh K, and Byrareddy SN (2021). Discovery and Evaluation of Entry Inhibitors for SARS-CoV-2 and Its Emerging Variants. *J Virol* 95, e0143721. [PubMed: 34550770]
- Acharya A, Pathania AS, Pandey K, Thurman M, Vann KR, Kutateladze TG, Challagundala KB, Durden DL, and Byrareddy SN (2022). PI3K-alpha/mTOR/BRD4 inhibitor alone or in combination with other anti-virals blocks replication of SARS-CoV-2 and its variants of concern including Delta and Omicron. *Clin Transl Med* 12, e806. [PubMed: 35390226]
- Adams PD, Grosse-Kunstleve RW, Hung LW, Ioerger TR, McCoy AJ, Moriarty NW, Read RJ, Sacchettini JC, Sauter NK, and Terwilliger TC (2002). PHENIX: building new software for automated crystallographic structure determination. *Acta crystallographica. Section D, Biological crystallography* 58, 1948–1954. [PubMed: 12393927]
- Dalvai M, Loehr J, Jacquet K, Huard CC, Roques C, Herst P, Cote J, and Doyon Y (2015). A Scalable Genome-Editing-Based Approach for Mapping Multiprotein Complexes in Human Cells. *Cell reports* 13, 621–633. [PubMed: 26456817]
- DeDiego ML, Alvarez E, Almazan F, Rejas MT, Lamirande E, Roberts A, Shieh WJ, Zaki SR, Subbarao K, and Enjuanes L (2007). A severe acute respiratory syndrome coronavirus that lacks the E gene is attenuated in vitro and in vivo. *Journal of virology* 81, 1701–1713. [PubMed: 17108030]
- Emsley P, and Cowtan K (2004). Coot: model-building tools for molecular graphics. *Acta crystallographica. Section D, Biological crystallography* 60, 2126–2132.
- Filippakopoulos P, and Knapp S (2014). Targeting bromodomains: epigenetic readers of lysine acetylation. *Nat Rev Drug Discov* 13, 337–356. [PubMed: 24751816]

- Filippakopoulos P, Picaud S, Mangos M, Keates T, Lambert JP, Barsyte-Lovejoy D, Felletar I, Volkmer R, Muller S, Pawson T, et al. (2012). Histone recognition and large-scale structural analysis of the human bromodomain family. *Cell* 149, 214–231. [PubMed: 22464331]
- Gilham D, Smith AL, Fu L, Moore DY, Muralidharan A, Reid SPM, Stotz SC, Johansson JO, Sweeney M, Wong NCW, et al. (2021). Bromodomain and Extraterminal Protein Inhibitor, Apabetalone (RVX-208), Reduces ACE2 Expression and Attenuates SARS-Cov-2 Infection In Vitro. *Biomedicines* 9.
- Gordon DE, Jang GM, Bouhaddou M, Xu J, Obernier K, White KM, O'Meara MJ, Rezelj VV, Guo JZ, Swaney DL, et al. (2020). A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. *Nature* 583, 459–468. [PubMed: 32353859]
- Jose L, Gilson T, Androphy EJ, and DeSmet M (2021). Regulation of the Human Papillomavirus Lifecycle through Post-Translational Modifications of the Viral E2 Protein. *Pathogens* 10.
- Kabsch W (2010). Xds. *Acta crystallographica. Section D, Biological crystallography* 66, 125–132.
- Klein BJ, Jang SM, Lachance C, Mi W, Lyu J, Sakuraba S, Krajewski K, Wang WW, Sidoli S, Liu J, et al. (2019). Histone H3K23-specific acetylation by MORF is coupled to H3K14 acylation. *Nature communications* 10, 4724.
- Kumar R, Mehta D, Mishra N, Nayak D, and Sunil S (2020). Role of Host-Mediated PostTranslational Modifications (PTMs) in RNA Virus Pathogenesis. *Int J Mol Sci* 22.
- Lambert JP, Picaud S, Fujisawa T, Hou H, Savitsky P, Uuskula-Reimand L, Gupta GD, Abdouni H, Lin ZY, Tucholska M, et al. (2019). Interactome Rewiring Following Pharmacological Targeting of BET Bromodomains. *Molecular cell* 73, 621–638 e617. [PubMed: 30554943]
- Li J, Lai S, Gao GF, and Shi W (2021). The emergence, genomic diversity and global spread of SARS-CoV-2. *Nature* 600, 408–418. [PubMed: 34880490]
- Marazzi I, Ho JS, Kim J, Manicassamy B, Dewell S, Albrecht RA, Seibert CW, Schaefer U, Jeffrey KL, Prinjha RK, et al. (2012). Suppression of the antiviral response by an influenza histone mimic. *Nature* 483, 428–433. [PubMed: 22419161]
- McCoy AJ, Grosse-Kunstleve RW, Adams PD, Winn MD, Storoni LC, and Read RJ (2007). Phaser crystallographic software. *Journal of applied crystallography* 40, 658–674. [PubMed: 19461840]
- Mills RJ, Humphrey SJ, Fortuna PRJ, Lor M, Foster SR, Quaife-Ryan GA, Johnston RL, Dumenil T, Bishop C, Rudraraju R, et al. (2021). BET inhibition blocks inflammation-induced cardiac dysfunction and SARS-CoV-2 infection. *Cell* 184, 2167–2182 e2122. [PubMed: 33811809]
- Murray LA, Combs AN, Rekapalli P, and Cristea IM (2019). Methods for characterizing protein acetylation during viral infection. *Methods in enzymology* 626, 587–620. [PubMed: 31606092]
- Netland J, DeDiego ML, Zhao J, Fett C, Alvarez E, Nieto-Torres JL, Enjuanes L, and Perlman S (2010). Immunization with an attenuated severe acute respiratory syndrome coronavirus deleted in E protein protects against lethal respiratory disease. *Virology* 399, 120–128. [PubMed: 20110095]
- Nieto-Torres JL, DeDiego ML, Verdía-Baguena C, Jimenez-Guardeno JM, Regla-Nava JA, Fernandez-Delgado R, Castano-Rodriguez C, Alcaraz A, Torres J, Aguilella VM, and Enjuanes L (2014). Severe acute respiratory syndrome coronavirus envelope protein ion channel activity promotes virus fitness and pathogenesis. *PLoS Pathog* 10, e1004077. [PubMed: 24788150]
- Qiao Y, Wang XM, Mannan R, Pitchiaya S, Zhang Y, Wotring JW, Xiao L, Robinson DR, Wu YM, Tien JC, et al. (2020). Targeting transcriptional regulation of SARS-CoV-2 entry factors ACE2 and TMPRSS2. *Proceedings of the National Academy of Sciences of the United States of America*.
- Qin S, Liu Y, Tempel W, Eram MS, Bian C, Liu K, Senisterra G, Crombet L, Vedadi M, and Min J (2014). Structural basis for histone mimicry and hijacking of host proteins by influenza virus protein NS1. *Nature communications* 5, 3952.
- Samelson AJ, Tran QD, Robinot R, Carrau L, Rezelj VV, Kain AM, Chen M, Ramadoss GN, Guo X, Lim SA, et al. (2022). BRD2 inhibition blocks SARS-CoV-2 infection by reducing transcription of the host cell receptor ACE2. *Nature cell biology* 24, 24–34. [PubMed: 35027731]
- Schoeman D, and Fielding BC (2019). Coronavirus envelope protein: current knowledge. *Virol J* 16, 69. [PubMed: 31133031]
- Shi J, Wang Y, Zeng L, Wu Y, Deng J, Zhang Q, Lin Y, Li J, Kang T, Tao M, et al. (2014). Disrupting the interaction of BRD4 with diacetylated Twist suppresses tumorigenesis in basal-like breast cancer. *Cancer cell* 25, 210–225. [PubMed: 24525235]

- Surya W, Li Y, and Torres J (2018). Structural model of the SARS coronavirus E channel in LMPG micelles. *Biochim Biophys Acta Biomembr* 1860, 1309–1317. [PubMed: 29474890]
- Verdia-Baguena C, Nieto-Torres JL, Alcaraz A, DeDiego ML, Torres J, Aguilera VM, and Enjuanes L (2012). Coronavirus E protein forms ion channels with functionally and structurally involved membrane lipids. *Virology* 432, 485–494. [PubMed: 22832120]
- Zhang Q, Zeng L, Shen C, Ju Y, Konuma T, Zhao C, Vakoc CR, and Zhou MM (2016). Structural Mechanism of Transcriptional Regulator NSD3 Recognition by the ET Domain of BRD4. *Structure* 24, 1201–1208. [PubMed: 27291650]
- Zhang Y, Ahn J, Green KJ, Vann KR, Black J, Brooke CB, and Kutateladze TG (2019). MORC3 Is a Target of the Influenza A Viral Protein NS1. *Structure* 27, 1029–1033 e1023. [PubMed: 31006586]

Highlights

The SARS-CoV-2 E protein is acetylated and interacts with BRD4 in human cells

Bromodomains (BDs) of BRD4 bind to the acetylated C-terminus of the E protein

The ET domain of BRD4 recognizes the unmodified motif of the E protein

Inhibitors of BRD4 decrease SARS-CoV-2 infectivity in lung cells




Figure 1. SARS-CoV-2 E protein is acetylated *in vivo* and interacts with BRD4.

(a) Domain architecture of BRD4 (top) and the SARS-CoV-2 E protein (bottom). Sequence alignment of the motif present in the E protein and other proteins known to interact with the BRD4 ET domain is shown on the right. Arrows indicate potential contacts between BRD4 and the E protein. Acetylated lysine residues are highlighted red. (b) Immunoprecipitation with anti-acetyl-lysine antibodies on whole cell extracts from 293T cells expressing FLAG-tagged SARS-CoV-2 E protein or empty tag (pcDNA3) followed by western blot with FLAG antibody indicates that SARS-CoV-2 E is acetylated *in vivo*. (c) Immunoprecipitation with anti-FLAG beads on the same extracts as in (b) followed by western blot with BRD4 antibodies indicates that the SARS-CoV-2 E protein interacts with BRD4 *in vivo*. (d) Acetylation efficiency of the SARS-CoV-2 E protein *in vitro*. Acetyltransferase assays using

recombinant p300 and the native human MYST-family HAT complexes purified via MEAF6 (MYST) or BRPF2 (HBO1) subunits and the SARS-CoV-2 E^{48–72} peptide (aa 48–72 of SARS-CoV-2 E) as the substrate. Incorporation of ³Hac was measured by liquid scintillation counting. Mock purification from K562 cells expressing an empty tag was used as control. Data are represented as mean ± SD between three replicates. (e) Acetyltransferase assays using recombinant p300 and H3 peptide (aa 1–29 of H3). Mock corresponds to a mock purification control. Data are represented as mean ± SD between three technical replicates. (f, g) Overlaid ¹H, ¹⁵N HSQC spectra of ¹⁵N-labeled BRD4 BD1 (f) and BRD4 BD2 (g) recorded before and after gradual addition of the indicated acetylated SARS-CoV-2 E peptides. The spectra are color-coded according to the protein:peptide molar ratio. See also Figures S1, S2 and S4.




Figure 2. Structural basis of SARS-CoV-2 E recognition by BRD4 BDs.

(a) A ribbon diagram of the crystal structure of BRD4 BD1 (green) in complex with the SARS-CoV-2 E^{K53ac/K63ac} peptide (aa 53–64 of SARS-CoV-2 E, yellow). Yellow dashed lines represent hydrogen bonds. (b) Electrostatic surface potential of BRD4 BD1 in complex with SARS-CoV-2 E^{K53ac/K63ac} (yellow ribbon), with blue and red colors representing positive and negative charges, respectively. (c) A ribbon diagram of the NMR structure of the homologous E protein from SARS-CoV (PDB ID: 5X29). An exposed C-terminal α -helix 3, consisting of residues K53-K63, is yellow. (d) Crystal structure of BRD4 BD1 (green) in complex with the SARS-CoV-2 E^{K63ac} peptide (aa 60–68 of SARS-CoV-2 E, orange). Red spheres represent water molecules. See also Figure S3.




Figure 3. The ET domain of BRD4 is an additional target of SARS-CoV-2 E.

(a) The SARS-CoV-2 E peptides tested. (b) Overlaid ^1H , ^{15}N HSQC spectra of the ^{15}N -labeled BRD4 ET domain recorded before and after gradual addition of the indicated SARS-CoV-2 E peptides. The spectra are color-coded according to the protein:peptide molar ratio. (c) Representative MST binding curves for the interaction of the BRD4 ET domain with the FAM-SARS-CoV-2 E⁵⁵⁻⁶⁶ peptide. Data are representative of two experiments, and error represents SEM. (d, e) Analysis of CSPs in the BRD4 ET domain induced by SARS-CoV-2 E⁵⁵⁻⁶⁶. Residues of the BRD4 ET domain that exhibited large chemical shift perturbations (greater than the average plus one standard deviation) upon addition of SARS-CoV-2 E⁵⁵⁻⁶⁶ are mapped onto the BRD4 ET structure (2JNS), labeled and colored orange in (d). Histogram of normalized CSPs in ^1H , ^{15}N HSQC spectra of BRD4 ET induced

by 10-fold molar excess of SARS-CoV-2 E⁵⁵⁻⁶⁶ as a function of residue is shown in (e). The dotted line indicates average chemical shift change plus one standard deviation. Side chain amide resonances are indicated by asterisk.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript




Figure 4. BRD4 inhibitors JQ1 and OTX015 block SARS-CoV-2 replication.

(a) Experimental diagram: the viral replication kinetics were measured in Calu-3 cells infected with SARS-CoV-2 (Delta variant of concern, pangolin lineage: B.1.617.2) with 0.5 MOI of viral titer and treated with JQ1 or OTX015. (b) Representative immunofluorescence images of infected (or uninfected negative control) Calu-3 cells probed with antibodies against the Spike glycoprotein of SARS-CoV-2 (green) in the absence (positive control) or presence of JQ1 and OTX015 at the indicated concentrations. Scale bar, 100 μ m for all panels. (c) Percent inhibition of SARS-CoV-2 infection in Calu-3 cells treated with JQ1 and OTX015 at the indicated concentrations. (d) Cell viability in compound treated and SARS-CoV-2 infected Calu-3 cells. Data in (c, d) represent mean of three replicates, and error bars represent SEM. $n=3$ Cells were from the same frozen stock, and experiments were

performed using the same plate on the same day. (e, f) Inhibition of SARS-CoV-2 replication in Calu-3 cells treated with JQ1 (e) or OTX015 (f). BRD4 inhibitor mediated effects on SARS-CoV-2 viral load were quantified in the culture supernatant using RT-qPCR and plotted as % inhibition of viral replication. Data in (e, f) represent mean of three independent measurements, and error bars represent SEM. n=3

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Table 1.

Diffraction data collection and refinement statistics for BRD4 BD1 in complex with acetylated SARS-CoV-2 E peptides.

	BRD4-BD1 in complex with monoacetylated SARS-CoV-2 E^{K63ac} peptide	BRD4-BD1 in complex with diacetylated SARS-CoV-2 E^{K53ac/K63ac} peptide
Data Collection		
Space group	C 2 2 21	P 21
Wavelength (Å)	1.54	1.54
Resolution (Å)	50.0–2.68 (2.81–2.68)*	48.11–2.60 (2.72–2.60)*
Unit-cell dimensions		
a, b, c (Å)	78.5, 91.4, 100.3	49.32, 96.22, 78.95
α, β, γ	90.0, 90.0, 90.0	90.00, 94.37, 90.00
No. of measured reflections	49963	41616
No. of unique reflections	10316 (1316)	22330 (2702)
Multiplicity	4.8 (4.4)	1.9 (1.8)
I/σ	14.6 (3.5)	5.7 (1.6)
Completeness (%)	98.9 (96.4)	98.5 (98.0)
R _{sym} [#] (%)	8.6 (49.7)	11.9 (40.4)
No. of molecules in ASU	2	4
Matthew's coefficient (Å ³ Da ⁻¹)	2.76	2.75
Solvent content (%)	55.4	55.3
Refinement		
R _{work} /R _{free} (%)	21.6/27.6 (33.8/38.1)	24.3/29.2 (32.2/40.9)
No. of atoms	2021	4996
Protein	1960	4758
Water	61	238
B-factors (Å ²)	4.0.89	25.34
Protein	41.12	25.52
Water	33.69	21.68
R.M.S.D		
Bond lengths (Å)	0.003	0.004
Bond angles (°)	0.58	0.73
Ramachandran favored (%)	97.8	98.0
Ramachandran allowed (%)	2.2	2.0
Ramachandran outliers	0	0
Clashscore	3.32	6.72

* Values in parentheses are for the highest resolution shell (Å).

[#]R_{sym} = $|I_{\text{obs}} - I_{\text{avg}}| / I_{\text{avg}}$, where I_{obs} is intensity of any given reflection and I_{avg} is the weighted mean I.

KEY RESOURCES TABLE

REAGENT or RESOURCE
Antibodies
Anti-Spike of SARS-CoV-2
AlexaFluor 488 Goat anti-rabbit
Anti-FLAG M2 agarose affinity gel (For IP)
Anti-acety-lysine (For IP)
Anti-FLAG M2 HRP conjugated (For WB)
Anti-Brd4 (For WB)
Bacterial and Virus Strains
Escherichia coli BL21-CodonPlus (De3) RIL
DH5 α Competent Cells
SARS-Related Coronavirus 2, Isolate hCoV-19/USA/MD-HP05647/2021
Chemicals, Peptides, and Recombinant Proteins
Dithiothreitol
β -mercaptoethanol
Imidazole
$^{15}\text{NH}_4\text{Cl}$
JQ1
OTX015
IPTG
Ni-NTA resin
Glutathione Sepharose 4B beads
Streptavidin magnetic beads
E peptides
PreScission protease
Thrombin protease
Enterokinase protease
Hoechst 33258
Cell Mask

REAGENT or RESOURCE
Recombinant p300 (catalytic domain)
Lipofectamine 3000
Critical Commercial Assays
Platinum™ II Hot-Start PCR Master Mix (2X)
QIAprep Spin Miniprep Kit
Deposited Data
Crystal structure of BRD4 Bromodomain 1 in complex with SARS-CoV-2 E peptide diacetylated at K53 and K63
Crystal structure of BRD4 Bromodomain 1 in complex with SARS-CoV-2 E peptide acetylated at K63
Experimental Models: Cell Lines
Calu-3 cells
K562
293T
Oligonucleotides
BamH1 E: atatagatccTACAGCTTCGTATCAGAAGA
Xho1 E: atatactcgagTCATTCGAGAACGAGGAGATC
gBlockE: TACAGCTTCGTATCAGAAGAAACCGGGACACTGATCGTAAATTCTGTGCTCTTGTTCCTGGCAATTCGTCGTAATTCCTCCGTCACACTGGCAATTCGAC
E_Sarbeco_F1: ACAGGTACGTTAATAGTTAATAGCGT
E_Sarbeco_R2: ATATTGCAGCAGTACGCACACA
E_Sarbeco_P1:FAM -ACACTAGCCATCCTTACTGCGCTTCG - BHQ1
Recombinant DNA
pGEX-6P-1
pGEX-4T-1
pcDNA3.1
Software and Algorithms
XDS
Phenix
Coot
Prism 9.0
CCP4
NMRPipe

REAGENT or RESOURCE
MO.Affinity Analysis
MO.Control software
Other
Quantitative PCR (qPCR) Control RNA from Heat-Inactivated SARS-Related Coronavirus 2, Isolate USA-WA1/2020
HiPrep™ 16/60 Sephacryl® S-100 HR column
HiTrap SP HP column
HiLoad Superdex 75 pg column

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript